News / Asia

Patent Dispute Threatens Access to Cheap Drugs in India

Indians suffering from HIV/AIDS attend a protest against the drugs manufacturer Novartis in New Delhi, India, January 29, 2007. Novartis is challenging a specific provision of the law that restricts the patenting of medicines to innovations only. Indians suffering from HIV/AIDS attend a protest against the drugs manufacturer Novartis in New Delhi, India, January 29, 2007. Novartis is challenging a specific provision of the law that restricts the patenting of medicines to innovations only.
x
Indians suffering from HIV/AIDS attend a protest against the drugs manufacturer Novartis in New Delhi, India, January 29, 2007. Novartis is challenging a specific provision of the law that restricts the patenting of medicines to innovations only.
Indians suffering from HIV/AIDS attend a protest against the drugs manufacturer Novartis in New Delhi, India, January 29, 2007. Novartis is challenging a specific provision of the law that restricts the patenting of medicines to innovations only.
Anjana Pasricha
NEW DELHI — A long running legal battle in India over drug patents could impact access to affordable, lifesaving drugs to millions of people across the globe. 

The case is being seen as a high stakes battle between drug companies supporting intellectual property rights and those who favor the production of cheap, generic drugs.   
Dr. Suniti Solomon has treated thousands of men and women suffering from HIV at her clinic in the southern city of Chennai since she detected India’s first AIDS infection 25 years ago. Affordable copies of brand name drugs produced by India’s booming generic drug industry have helped her patients enormously.   
 
“Earlier, when we did not have generic drugs, maybe one or two percent of my patients could afford the drugs from abroad," Solomon said. "Now, 60 to 70 percent can easily afford at least the first line drugs which keep them alive for maybe ten years or longer.”
 
Like the patients in Chennai, these generic drugs are a lifeline for millions of people in Africa and other developing countries.
 
Many of them are not aware of it, but a case pending before the Indian Supreme Court could have a far reaching impact on their access to these inexpensive drugs. 

It involves a legal challenge by Swiss pharmaceutical company Novartis to India’s refusal to grant a patent for a medicine used to treat leukemia. It has been winding its way through the Indian courts for almost six years. Final arguments will be heard next month.  
 
India denied a patent for Gleevec saying that it is not a new medicine but a salt formulation of a known drug. India does not allow companies to patent modifications of an old medicine unless its efficacy is significantly improved.
 
Forty countries, including the United States, China and Russia, have granted a patent for Gleevec. But in India, its generic version is being produced at a fraction of the cost.
 
Novartis says it is seeking clarity on how innovation by the drug industry will be protected in India. Ranjit Shahani, who heads the India operations of Novartis, says inadequate patent protection will discourage innovators.  
 
“The long road to innovation research is fraught with risks and huge costs," Shahani said. "Only one out of ten thousand experimental compounds in development will reach the marketplace and the cost is between one to two billion dollars for each medicine approved. A successful molecule that makes it as a drug needs to pay for thousands of those molecules that fail.”
 
The case has attracted international attention. The multinational drug industry sees the Indian law as a way of circumventing patent rights and wants more stringent standards.
 
However, supporters of India’s patent law say that it prevents a practice called “evergreening,” in which drug companies get new patents by making minor changes to older ones and stave off generic competition.
 
Leena Menghaney, a lawyer with Doctors Without Borders in New Delhi, calls it a test case.   
 
“If Novartis wins, it can have a huge chilling effect on generic production. Once patenting standards are lowered, that means more patents are granted on drugs, that means less number of drugs generic companies will be able to manufacture. So it has implications across the board for all essential medicines, particularly for HIV,” Mengheny said.
 
Health activists fear that a ruling in favor of Novartis may drastically reduce the global supply of inexpensive, generic drugs being used to treat people suffering from deadly diseases. They say if costs rise greatly, voluntary groups across the world will have to significantly scale down programs assisting patients who cannot afford lifesaving medicines.
 
One such patient is a 23-year-old student in Mumbai, Siddhesh Tilekar. Since he was diagnosed with cancer about three years ago, he gets drugs from a local cancer support group.
 
“We cannot afford that much of cost," Tilekar said. "If my family spends on my medicine, it is very difficult for us to survive.”
 
Multinational drug companies are worried about other provisions in India’s patent law.

Earlier this year, India allowed a domestic company to manufacture an expensive anti-cancer drug developed by Bayer Corporation using a rule under which a license can be granted if a drug is not available at a “reasonably affordable price.”  
 
According to Ranjit Shahani at Novartis, protecting patents is critical.
 
“The reality is without patents there will be no new drugs and without new drugs there will be no generics," he said. "So if innovation is not protected, it is the patient who will be the ultimate loser.”
 
Lawyers say there are also worries that India’s patent laws could become a model for other developing countries, limiting the multinational drug industry’s access to these fast-growing markets.

You May Like

US Imposes Sanctions on Alleged Honduran Drug Gang

Treasury department alleges Los Valles group is responsible for smuggling tens of thousands of kilograms of cocaine into US each month More

At 91, Marvel Creator Stan Lee Continues to Expand his Universe

Company's chief emeritus hopes to interest new generation of children in superheroes of all shapes and sizes by publishing content across multiple media platforms More

Photogallery New Drug Protects Against Virus in Ebola Family

Study by researchers at University of Texas Medical Branch, Tekmira Pharmaceuticals is first looking at drug's effectiveness after onset of symptoms More

This forum has been closed.
Comment Sorting
Comments
     
by: patent litigation from: Mexico
July 23, 2012 4:01 AM
Compulsory licensing is a contemporary necessity, and I'm glad to see countries from Australian to China implementing this model. I, for one, am heartened not only by the Indian Patent Office's recent decision to grant a compulsory license, but also by the further news that India now has plans to distribute some life-saving drugs for free. That -- and not gouging suffering patients at every possible opportunity -- seems to me to be the epitome of corporate responsibility.
http://www.generalpatent.com/blog


by: C Karen Stopford from: Connecticut
July 21, 2012 8:38 AM
What the pharmaceutical companies are saying is patently (no pun intended) false. Not every country lives by the American ethos of "profit at all costs." Why, believe it or not, there are some places in the world where human life has a value greater than a big credit limit. And innovation occurs in these places because people are respected, valued, allowed to explore and learn and satisfy their curiosity, and because people want to help other people. In fact, that's where most innovations come from. Not in America, of course - but elsewhere. Our system is cruel, unjust, immoral and unethical - and we will bully every other country in the world to do as we do - or else. Let 'em die! We need a profit!

Featured Videos

Your JavaScript is turned off or you have an old version of Adobe's Flash Player. Get the latest Flash player.
African Media Tries to Educate Public About Ebolai
X
George Putic
August 20, 2014 8:57 PM
While the Ebola epidemic continues to claim lives in West Africa, information technology specialists, together with radio and TV reporters, are battling misinformation and prejudice about the disease - using social media to educate the public about the deadly virus. VOA’s George Putic has more.
Video

Video African Media Tries to Educate Public About Ebola

While the Ebola epidemic continues to claim lives in West Africa, information technology specialists, together with radio and TV reporters, are battling misinformation and prejudice about the disease - using social media to educate the public about the deadly virus. VOA’s George Putic has more.
Video

Video Ferguson Calls For Justice as Anger, Violence Grips Community

Violence, anger and frustration continue to grip the small St. Louis suburb of Ferguson, Missouri. Protests broke out after a white police officer fatally shot an unarmed black teenager on August 9. The case has sparked outrage around the nation and prompted the White House to send U.S. Attorney Eric Holder to the small community of just over 20,000 people. VOA’s Mary Alice Salinas has more from Ferguson.
Video

Video Beheading Of US Journalist Breeds Outrage

U.S. and British authorities have launched an investigation into an Islamic State video showing the beheading of kidnapped American journalist James Foley by a militant with a British accent. The extremist group, which posted the video on the Internet Tuesday, said the murder was revenge for U.S. airstrikes on militant positions in Iraq - and has threatened to execute another American journalist it is holding. Henry Ridgwell has more from London.
Video

Video Family Robots - The Next Big Thing?

Robots that can help us with daily chores like cooking and cleaning are a long way off, but automatons that serve as family companions may be much closer. Researchers in the United States, France, Japan and other countries are racing to build robots that can entertain and perform some simpler tasks for us. VOA’s George Putic reports.
Video

Video In Ukraine, Fear and Distrust Remain Where Fighting has Stopped

As the Ukrainian military reclaims control of eastern cities from pro-Russian separatists, residents are getting a chance to rebuild their lives. VOA's Gabe Joselow reports from the town of Kramatorsk in Donetsk province, where a sense of fear is still in the air, and distrust of the government in Kyiv still runs deep.
Video

Video Five Patients Given Experimental Ebola Drug Said to Be Improving

The World Health Organization has approved the use of experimental treatments for Ebola patients in West Africa. The Ebola outbreak there is unprecedented, the disease deadly. The number of people who have died from Ebola has surpassed 1,200. VOA's Carol Pearson reports on the ethical considerations of allowing experimental drugs to be used.
Video

Video China Targets Overseas Assets of Corrupt Officials

As China presses forward with its anti-graft effort, authorities are targeting corrupt officials who have sent family members and assets overseas. The efforts have stirred up a debate at home on exactly how many officials take that route and how likely it is they will be caught. Rebecca Valli has this report.
Video

Video Leading The Fight Against Islamic State, Kurds Question Iraqi Future

Western countries including the United States have begun arming the Kurdish Peshmerga forces in northern Iraq to aid their battle against extremist Sunni militants from the Islamic State. But there are concerns that a heavily-armed Kurdistan Regional Government, or KRG, might seek to declare independence and cause the break-up of the Iraqi state. As Henry Ridgwell reports from London, the KRG says it will only seek greater autonomy from Baghdad.
Video

Video In Rural Kenya, Pressure Builds Against Female Circumcision

In some Kenyan communities, female genital mutilation remains a rite of passage. But activists are pushing back, with education for girls and with threats of punishment those who perform the circumcision. Mohammed Yusuf looks at the practice in the rural eastern community of Tharaka-Nithi.

AppleAndroid